Can-Fite BioPharma (CANF) EBT (2014 - 2023)
Can-Fite BioPharma's (CANF) quarterly EBT came in at -$28.5 million in Q4 2023, down 2.89% YoY from -$29.3 million in Q4 2022, and down 1427.94% on a QoQ basis from -$1.9 million in Q3 2023.
Can-Fite BioPharma (CANF) EBT (2014 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of EBT data on file, last reported at -$28.5 million in Q4 2023.
- Quarterly EBT fell 2.89% year-over-year to -$28.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$35.8 million (down 3.23% YoY) and the FY2025 annual result came in at -$9.8 million, down 24.72% from the prior year.
- EBT slipped to -$28.5 million in Q4 2023, from -$1.9 million in the prior quarter.
- In the past five years, EBT ranged from a high of $1.6 million in Q1 2019 to a low of -$28.5 million in Q4 2023.
- A 5-year average of -$5.5 million and a median of -$2.7 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2019 — EBT tumbled 745.11% — and 2021, when it soared 49.23%.
- Tracing CANF's EBT over 5 years: stood at -$2.1 million in 2019, then sank by 106.85% to -$4.3 million in 2020, then tumbled by 54.28% to -$6.7 million in 2021, then sank by 312.87% to -$27.7 million in 2022, then fell by 2.89% to -$28.5 million in 2023.
- The last three EBT figures came in at -$28.5 million (Q4 2023), -$1.9 million (Q3 2023), and -$2.8 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -28.50 Mn |
| Sep 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -2.76 Mn |
| Mar 31, 2023 | -2.71 Mn |
| Dec 31, 2022 | -27.70 Mn |
| Sep 30, 2022 | -2.57 Mn |
| Jun 30, 2022 | -2.07 Mn |
| Mar 31, 2022 | -2.37 Mn |
| Dec 31, 2021 | -6.71 Mn |
| Sep 30, 2021 | -3.40 Mn |
| Jun 30, 2021 | -3.13 Mn |
| Mar 31, 2021 | -2.17 Mn |
| Dec 31, 2020 | -4.35 Mn |
| Sep 30, 2020 | -2.58 Mn |
| Jun 30, 2020 | -3.83 Mn |
| Mar 31, 2020 | -4.28 Mn |
| Dec 31, 2019 | -2.10 Mn |
| Sep 30, 2019 | -2.25 Mn |
| Jun 30, 2019 | -6.15 Mn |
| Mar 31, 2019 | 1.57 Mn |